[Treatment with autologous tumor-infiltrating lymphocytes and recombinant interleukin-2 in patients with lung carcinoma].
In 16 patients with lung cancer tumor infiltrating Lymphocytes (TIL) and peripheral blood lymphocytes (PBL) and their antitumor activities after IL-2 activation and were tested by 3H-TdR releasing assay. The results showed that the cytolytic activity of TIL against autologous tumor cells was lower than of IL-2 activated PBL (LAK cells) at the early incubation period but become markedly higher than that of LAK cells when the incubation lasted for 20 to 25 days. The subjectively most patients received systemic TIL treatment felt better and their immune functions were improved. Transiant Low-grade fever occurred in cases and drop of arterial blood pressure in 1. No potentially fatal toxic effect was observed.
Li
D
D
Department of Digestive Medicine, Second Teaching Hospital, Bethune University of Medical Sciences, Changchun.
Zhang
X
X
Song
Y
Y
D000230:Adenocarcinoma / Q000276:immunology / Q000628:therapy; D000328:Adult; D000368:Aged; D002294:Carcinoma, Squamous Cell / Q000276:immunology / Q000628:therapy*; D005260:Female; D006801:Humans; D016219:Immunotherapy, Adoptive; D007376:Interleukin-2 / Q000627:therapeutic use*; D015979:Killer Cells, Lymphokine-Activated / Q000637:transplantation; D008175:Lung Neoplasms / Q000276:immunology / Q000628:therapy*; D016246:Lymphocytes, Tumor-Infiltrating / Q000637:transplantation*; D008297:Male; D008875:Middle Aged; D011184:Postoperative Period; D011994:Recombinant Proteins / Q000627:therapeutic use
D007376:Interleukin-2; D011994:Recombinant Proteins